Sodium valproate (Episenta®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000352
English
Authors' recommendations:
Sodium valproate (Episenta®) is recommended as an option for use within NHS Wales for the treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. The continuation of treatment after manic episode could be considered in patients who have responded to sodium valproate (Episenta®) for acute mania.
AWMSG is of the opinion that sodium valproate (Episenta®) may be suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=184839&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Bipolar Disorder
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.